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a b s t r a c t
Aims: Secondhand smoke (SHS) exposure is associatedwith elevatedCHD risks. Yet the pathways through
which thismay operate have not been investigated in epidemiologic studieswith objective SHS exposure
measures and a wide range of CHD risk factors associated with active smoking. Therefore we investigate
associations between SHS exposure and CHD risk factors, to clarify how SHS exposure may raise risk of
CHD.
Methods: Cross-sectional population-based study of 5029 men and women aged 59–80 years from pri-
mary care practices in Great Britain. Smoking, behavioural and demographic information was reported
in questionnaires; nurses made physical measurements and took blood samples for analysis of serum
cotinine and markers of inﬂammation, hemostasis and endothelial dysfunction.
Results: Active cigarette smokers had lower albumin and higher triglycerides, CRP, IL-6, white cell count,
ﬁbrinogen, blood viscosity, factor VIII, VWF and t-PA than non-smokers. Among non-smokers, serum
cotinine levels were independently positively associated with CRP, ﬁbrinogen, factor VIII, VWF and t-PA
and inversely associated with albumin, after adjustment for age, gender, social and behavioural factors.
The differences in CRP, ﬁbrinogen and albumin between cotinine ≤0.05 and >0.7ng/ml were one-third
to one half the size of differences between cotinine ≤0.05ng/ml and current smokers, but were of similar
magnitude for VWF and t-PA.
Conclusions: Endothelial, inﬂammatory and haemostatic markers related to CHD risk showed indepen-
dent associations with SHS exposure in the same direction as those for active smoking. Results aid
ciatiunderstanding of the asso. Introduction
Secondhand smoke (SHS) is associated with elevated risks of
oronary heart disease (CHD) [1–3] and stroke [4]. Epidemiologic
Abbreviations: SHS, secondhand smoke; MI, myocardial infarction; CVD, car-
iovascular disease; CHD, coronary heart disease; CI, conﬁdence interval; HDLc,
igh density lipoprotein cholesterol; CRP, C-reactive protein; IL-6, interleukin-6; IL-
8, interleukin-18; VWF, vonWillebrand factor; TNF, tumor necrosis factor-alpha;
MP-9, matrix metalloproteinase-9; BMI, body mass index; BP, blood pressure;
BP, systolic blood pressure; DBP, diastolic blood pressure; t-PA, tissue plasminogen
ctivator; LR, likelihood ratio.
∗ Corresponding author at: UCL Deptartment Primary Care & Population Health,
CL Medical School, Rowland Hill St, NW3 2PF, London. Tel.: +44 0207 830 2230;
ax: +44 020 7794 122.
E-mail address: b.jefferis@pcps.ucl.ac.uk (B.J. Jefferis).
021-9150/$ – see front matter © 2009 Elsevier Ireland Ltd. All rights reserved.
oi:10.1016/j.atherosclerosis.2009.07.044ons between SHS exposure and elevated CHD risks.
© 2009 Elsevier Ireland Ltd. All rights reserved.
studies based on self-reported exposure to SHS have reported a
1.2- to 1.3-fold increase in risk of CHD, independent of established
CHD risk factors [2,3]; whilst a study using serum cotinine as a
marker of overall SHS exposure reported slightly higher hazard
ratios, around 1.4 [5]. In both types of study, the risks associated
with high SHS exposure were very similar to risks from light active
smoking, despite the much greater exposure to tobacco smoke in
active smoking [1,5,6]. However, the mechanisms by which SHS
elevates CHD risk remain uncertain. Several possible pathways are
indicated by experimental studies in adults; acute SHS exposure
has been shown to increase platelet activity [7,8], lower HDL-
cholesterol (HDLc) levels [9], elevate homocysteine levels [10], or
increase circulating levels of inﬂammatory and hemostatic mark-
ers which are themselves associated with CHD risk, such as white
cell count [11]. Experimental data also suggest that SHS may cause
endothelial damage, increasing endothelial cell turnover [7] and
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ausing a similar degreeof endothelial dysfunction to that observed
n active smokers [12]. Active cigarette smoking inﬂuences all these
athways [13–16].
Whilst most evidence about how SHS affects cardiovascular
isk factors comes from short-term laboratory studies [3], evidence
bout the relationof SHSexposure to the riskpathways at thepopu-
ation level is limited. Most epidemiologic studies of SHS exposure
nd CHD risk factors rely on self-report [17]. To date cotinine, a
uantitativemarker of recent tobacco exposure [18], has been used
omeasure SHS exposure in relation to CHD risk factors in only two
opulation-based studies, the British Regional Heart Study and the
hird National Health and Nutrition Examination Survey (NHANES
II) [5,19,20]. Population studies indicate that SHS exposure (either
elf-report or cotinine level) is associated with signiﬁcantly higher
ystolic and diastolic blood pressure (SBP and DBP), BMI [5,20]
nd homocysteine levels [17,19], although associations with lipids
19–21], white blood cell count, C-reactive protein (CRP) and ﬁb-
inogen [17,19,22] are less consistent.
In order to examine potential pathways linking SHS exposure
o CHD risk, we examine the epidemiological associations between
HS exposure, assessed by serum cotinine, with a wide range of
ctivation markers of inﬂammation and hemostasis that existing
ata suggest could be part of the response to SHS exposure and are
mplicated in CHD risk in older men and women. Analyses exam-
ne the effect of adjustment for important confounders and set the
ssociations between SHS exposure and risk factors in the context
f associations observed in active smokers. We exclude from anal-
ses ex-smokers who quit recently (to avoid carry over effects),
articipants taking warfarin (which would affect levels of coagu-
ation factors) and participants with a history of MI, diabetes or
troke, to avoid reverse causality.
. Methods
.1. Study design
Two parallel prospective studies of 60–79 year olds: 4252 men
urveyed in 1998–2000 and 4286 women surveyed in 1999–2001.
articipantswere froma singleGeneral Practice in 24British towns,
7% response rate (men) [23] and 60% (women) [24]. Near identi-
al protocols for data collection were used. Participants completed
etailed questionnaires including health behaviour data. Nurses
ade physical measurements and collected fasting venous blood
amples (see supplementary data). All participants provided writ-
en informed consent to the investigation and ethical approval was
rovided by all relevant local Research Ethics Committees.
.2. Laboratory assays
Liquid chromatography tandem mass spectrometry was used
o assay cotinine in serum samples of non-smokers, the unit of
uantiﬁcation was 0.1ng/mL and the lower limit of detection was
.02ng/mL. Cotinine values at the limit of quantiﬁcation (0.1) were
ssigned a value of 0.05ng/ml. Further details, including assays for
lood lipids and metabolic markers, inﬂammatory and hemostatic
arkers are described in supplementary data.
.3. Classiﬁcation of smokers and non-smokers
Non-smokers reported no current cigarette, cigar or pipe smok-
ng or any smoking in the past 5 years, and had serum cotinine
15ng/mL, consistent with other literature [25]. 99% of self-
eported non-smokers with cotinine data had levels <15ng/mL, 76
on-smokers with cotinine >15ng/mL were recoded as smokers
f 1–9 cigarettes/day. No participants reported taking nico-sis 208 (2010) 550–556 551
tine replacement therapy (British National Formulary code 4.10)
[26].
2.4. Statistical methods
Serumcotininewas highly positively skewed and therefore ana-
lyzedas categories, thehighest exposure groupwas chosenbecause
cotinine >0.7ng/mL is reportedly associated with elevated CHD
risks [5], the lowest group had undetectable exposure and par-
ticipants with intermediate exposure were split into two equal
groups. Cotinine was also natural log transformed to base 2 to
display the effect of doubling in cotinine level. Means or propor-
tions of behavioural and demographic factors selected a prioriwere
calculated for groups of non-smokers (deﬁned by cotinine level)
and active smokers (deﬁned by cigarettes/day). P values for lin-
ear trends in cotinine levels in non-smokers were obtained using
linear or logistic regression analyses of each of the behavioural or
demographic variables, with log2[cotinine] as a predictor, adjusted
for age, gender and region of residence. CVD markers were exam-
ined: skewed variables were natural log-transformed and adjusted
for time of measurement if they showed signiﬁcant diurnal vari-
ation. BP, BMI and waist circumference were also adjusted for
intra-observer variation. No diurnal or seasonal (October–March
vs April–September) variation in cotinine levels was observed.
The percentage change between the mean CVD marker levels
for non-smokers in the lowest compared with highest coti-
nine categories were calculated as [(mean ≤0.05ng/mL)− (mean
0.71–15ng/mL)/mean ≤0.05ng/mL]. Percentage differences were
also calculated comparing non-smokerswith≤0.05ng/mL cotinine
to smokers (1–9 cigarettes/day).
Linear regression models were used to estimate the linear
associations between each inﬂammatory, endothelial or hemo-
static marker (response variable) and log2[cotinine], so the beta
coefﬁcients represent the risk factor difference associated with a
doubling in cotinine concentration. Models were ﬁrst adjusted for
age, gender and region of residence, and next for physical inac-
tivity, light alcohol drinking, smoking history (time since quitting
smoking or never-smoking) and social class as categorical variables
and BMI as a continuous variable. Interaction terms between BMI
and gender were ﬁtted for the inﬂammatory markers where inter-
actions were evident (likelihood ratio (LR) test P<0.05). Finally,
adjustments were made for HDLc, triglycerides and SBP as con-
tinuous variables. Further, logistic regression models contrasted
cotinine ≤0.05 with >0.7ng/mL, because cotinine >0.7ng/mL was
reportedly associated with elevated CHD risks [5]. Age and gender
were examined as modiﬁers of the cotinine-CVD marker asso-
ciations. Interactions were tested using LR tests. As sensitivity
analyses, models were restricted to (i) never-smokers and (ii) par-
ticipants with cotinine ≤9.5ng/mL.
3. Results
Among 8152 participants (4267 women, 4245 men) with ques-
tionnaire data on cigarette smoking, 90% (n=7375) had cotinine
assays. The analysis sample excluded (i) n=251 (3%) ex-smokers
who quit <5 years previously, (ii) 162 taking warfarin (iii) 1472
with a history (self-report or record in GP notes) of MI, diabetes
or stroke, (iv) 733 active cigarette smokers. The analysis sam-
ple comprised 4757 non-smokers (of which 52% never smoked).
For comparison, descriptive analyses included 272 smokers of 1–9
cigarettes/day. Of 4757 non-smokers, 38% had undetectable coti-
nine (≤0.05ng/mL) and the remainder were divided into three
groups (Table 1).
The characteristics of active smokers and non-smokers with
different levels of SHS exposure are shown in Table 1. Geomet-
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Table 1
Association between serum cotinine in non and active smokers and demographic or behavioural factors [mean or %]a.
Non-smokers (serum cotinine ng/mL) Cigarette
smokers
P (trend) b P (no difference)b
N ≤0.05 0.06–0.19 0.20–0.70 0.71–15 (1–9/day) In non-smokers ≤0.05ng/mL vs
smokers
(n=1994) (n=1130) (n=1034) (n=599) (n=272)
Age (years) 5029 69.3 68.4 68.0 67.9 69.1 <0.001 0.470
Women (%) 5029 62.5 55.0 48.7 44.4 59.9 <0.001 0.310
Northern region of residence (%) 5029 33.2 39.5 40.8 46.1 41.9 <0.001 <0.001
Manual occupational class (%) 4735 41.2 44.9 56.3 65.7 56.3 <0.001 <0.001
Light alcohol consumption (1–15 units/week) 4499 39.5 43.8 45.2 39.4 39.8 0.777 0.868
Quit smoking >20 years ago (%) 4757 27.2 26.1 28.6 29.6 – 0.770 –
Never smokers (%) 4757 57.2 55.2 47.7 39.7 – <0.001 –
9.6
g war
ge, ge
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A
gLow physical activity (<3h moderate/vigorous/week) 4848 62.1 5
a Sample excludes participants (i) with prevalent diabetes, stroke or MI, (ii) takin
b P-value from regression model of each factor with log2[cotinine], adjusted for a
ic mean cotinine was much higher in smokers than non-smokers;
00.58ng/mL vs 0.15ng/mL, P<0.001. Active smokers tended to
e from manual social groups, resident in the north of the UK, and
hysically inactive.Non-smokerswithhigher comparedwith lower
erum cotinine levels (greater SHS exposure), were also fromman-
al social class groups, resident in the north of the UK, physically
able 2
ssociation between serum cotinine in non-smokers and active smokers with cardiovasc
Non-smokers (serum cotinine ng/mL)
N ≤0.05 0.06–0.19 0.20–0.7
(n=1994) (n=1130) (n=1034
Blood pressure
Systolic (mm/Hg)b,c 5000 148.82 147.74 147.31
Diastolic (mm/Hg)b,c 5000 82.92 82.40 82.73
Lipids
Total cholesterol (mMol/L) 5001 6.39 6.37 6.35
HDL cholesterol (mMol/L) 4989 1.53 1.51 1.52
Triglyceride (mMol/L)c,d 4868 1.56 1.57 1.55
Metabolic markers
Body mass index (Kg/m2) 4488 26.70 27.11 27.34
Waist circumference (cm) 4394 90.22 91.35 91.58
Insulin (u/L)c,d 4891 6.91 7.04 6.94
Glucose (mMol/L)c,d 4850 5.66 5.63 5.64
Inﬂammatory/hemostatic markers
C-reactive protein (mg/L)d 4961 1.41 1.49 1.60
IL-6 (pg/mL)d 4994 2.16 2.19 2.28
White cell count (1ˆ09/L)c,d 4793 6.60 6.61 6.60
Albumin (g/L)c 4868 44.33 44.20 44.08
Fibrin D-dimer (ng/mL)d 5012 83.18 83.73 84.96
Plasma viscosity (mPa s)c 4720 1.28 1.29 1.28
Blood viscosity (mPa s)c,d 4624 1.55 1.56 1.56
Fibrinogen (g/L)c 4875 3.19 3.18 3.22
Factor VII (IU/dL)c 4868 133.51 132.89 133.07
Factor VIII (IU/dL) 5011 141.72 144.08 145.09
Von Willebrand factor (IU/dL) 5014 137.20 140.39 142.85
t-PA (ng/mL)c 4880 9.26 9.43 9.70
Mean platelet volume (fL) 4852 8.74 8.72 8.73
Hematocrit (%) 4921 45.25 45.19 45.12
Platelet count (1ˆ09/L) 4921 246.67 245.94 248.39
Homocysteine (mol/L) 2224 12.87 13.00 12.72
IL-18 (pg/mL)d 1607 369.13 365.01 385.78
CD40 Ligand (pg/mL)d 1614 5.42 5.23 5.32
MMP-9 (ng/mL)d 1614 448.93 483.14 452.90
TNF (pg/mL)d 1595 1.73 1.84 1.77
a Sample excludes participants (i) with pre-existing diabetes, stroke or MI, (ii) taking
ender and region of residence
b Adjusted for intra-observer variation
c Adjusted for time of day
d Geometric mean
e P-value for trend from linear regression models in non-smokers of each marker with
f P-value for difference between cotinine ≤0.05ng/mL and smokers (≥1cigarette/day),59.8 60.9 73.4 0.008 <0.001
farin and (iii) ex-smokers who quit <5 years ago.
nder and region.
inactive and were younger, male, ex-smokers rather than never-
smokers.Table 2 presents adjusted mean values of CVD risk markers for
active smokers and non-smokers with different levels of SHS expo-
sure, compared to the non-smokers with cotinine ≤0.05ng/mL.
Active smokers had lower BMI, fasting insulin and albumin
ular risk factorsa.
Cigarette
smokers
P (trend)e P (no difference)f
0 0.71–15 (1–9/day) In non-smokers ≤0.05ng/mL vs smokers
) (n=599) (n=272)
150.08 146.23 0.774 0.070
83.90 81.60 0.305 0.059
6.37 6.37 0.976 0.743
1.53 1.49 0.193 0.112
1.60 1.68 0.089 0.008
27.37 25.62 <0.001 <0.001
92.06 89.10 <0.001 0.160
7.35 6.29 0.028 0.009
5.63 5.59 0.833 0.095
1.78 2.29 <0.001 <0.001
2.41 3.05 <0.001 <0.001
6.66 7.76 0.175 <0.001
43.87 43.59 <0.001 <0.001
80.60 100.30 0.846 0.001
1.29 1.30 0.009 0.006
1.57 1.58 0.007 0.006
3.28 3.49 0.026 <0.001
135.82 136.00 0.052 0.172
148.83 144.63 <0.001 0.173
144.05 146.86 <0.001 <0.001
10.04 10.05 <0.001 0.001
8.76 8.61 0.497 0.269
44.90 45.43 0.193 0.332
251.35 262.83 0.065 <0.001
13.49 14.43 0.100 0.013
380.73 389.93 0.196 0.287
5.61 6.09 0.318 0.029
474.47 571.03 0.219 <0.001
1.82 1.91 0.426 0.116
warfarin and (iii) ex-smokers who quit <5 years ago. Means are adjusted for age,
log2[cotinine] adjusted for age, gender and region.
from logistic regression models of each marker adjusted for age, gender and region.
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bFig. 1. Associations between serum cotinine level in non-smokers, or ac
ompared with non-smokers with cotinine ≤0.05ng/mL. Smokers
ad higher triglycerides, CRP, IL-6, white blood cell count, ﬁb-
in D-dimer, plasma and blood viscosity, ﬁbrinogen, VWF, t-PA,
latelet count, homocysteine, CD40 Ligand andMMP-9. The largest
ercentage differences in CVD risk factor between smokers and
on-smokers with cotinine ≤0.05ng/mL were for CRP (62%), IL-6
41%),MMP-9 (27%)ﬁbrinD-dimer (21%) andwhitebloodcell count
18%). Active smoking was not appreciably associated with blood
ressure, waist circumference, total and HDL cholesterol, glucose,
ean platelet volume, factor VII, factor VIII, haematocrit, IL-18 or
NF levels.
Among non-smokers, higher cotinine levels were associated
ith higher BMI, waist circumference, fasting insulin, CRP, IL-
, blood and plasma viscosity, ﬁbrinogen, factor VIII, VWF, t-PA
nd with lower albumin (Table 2, Fig. 1a–d). Modest associa-
ions with factor VII, triglycerides and platelet count did not reach
onventional levels (5%) of statistical signiﬁcance; there were no
ssociations with BP, fasting lipids and glucose, white cell count,
brin D-dimer, mean platelet volume, haematocrit, homocysteine,
L-18, CD40L, MMP-9 and TNF. Among non-smokers the largest
ercentage changes in CVD risk factors in participants with coti-
ine >0.7ng/mL compared with ≤0.05ng/mL were for CRP (26%),
L-6 (12%) and t-PA (9%).
Table 3 presents associations in non-smokers between
og2[cotinine] and each risk factor in models adjusted ﬁrst for gen-
er, age and region of residence, then additionally for social and
ehavioural confounders including smoking history and BMI. The
oefﬁcients represent the risk factor difference associated with a
oubling in cotinine concentration. Among factors where associa-
ions with increasing SHS exposure were in the same direction as
ssociations with active smoking in earlier analyses, on full adjust-
ent, CRP, IL6, ﬁbrinogen, factor VIII, VWF, t-PA and albumin were
till associatedwith cotinine, although adjustments attenuated the
trengths of associations by up to half (for CRP, IL-6 and t-PA) and
p to a quarter (albumin and factor VIII). Adjusted associations
etween cotinine level and blood and plasma viscosity were atten-mokers of 1–9 cigarettes/day and (a) CRP (b) VWF (c) t-PA (d) Albumin.
uated to the null. Cotinine levels were not consistently associated
with BP, lipids, insulin or glucose, white cell count, ﬁbrin D-dimer,
mean platelet volume, platelet count, haematocrit, homocysteine,
IL-18, CD40 ligand, MMP-9 or TNF, after adjustment for health
behaviours, social class and BMI. Additional adjustments for lipids
and BP did not materially affect results except for IL-6, which was
attenuated to the null. Treating cotinine as a dichotomous variable,
(>0.7ng/ml compared to ≤0.05) yielded similar results.
Restricting analyses in Table 3 to never-smokers (n=2496)
reduced precision; associations of cotinine with BMI, CRP, IL-6
and albumin were of similar magnitude to those reported above
for all current non-smokers but conﬁdence intervals were wide
and included the null value. Associations with waist circumference
and ﬁbrinogen were not found in never-smokers. Other signiﬁcant
associations between cotinine and risk markers were not materi-
ally changed by restriction to never-smokers, or to non-smokers
with cotinine ≤9.5ng/mL. Variables which were robustly associ-
ated with cotinine (Table 3), showed similar associations in both
sexes and did not vary by age in regression models with cotinine
as a continuous or a dichotomous variable (all LR tests of interac-
tions, P>0.05). Sensitivity analyses using 0.025 and 0.075 rather
than 0.05ng/ml for undetectable cotinine gave a similar pattern of
results.
4. Discussion
Several cardiovascular risk factors showed independent associ-
ations with SHS exposure in the same direction as active smoking,
adjusted for age, gender, social and behavioural factors. These
included CRP, ﬁbrinogen, factor VIII, VWF and t-PA (all ofwhich had
higher circulating levels both with active smoking and SHS expo-
sure). Although active smokers had higher triglyceride and insulin
levels and lower mean BMI and waist circumference than non-
smokers with low SHS exposure, these factors did not show similar
patterns of associations with SHS exposure in adjusted analyses.
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Table 3
Association between cardiovascular risk factors and serum cotinine in non-smokers. The ﬁgures represent the risk factor difference associated with a doubling in cotinine
concentration.
N Model 1 = age+ region+gender Model 2 =Model 1 +health behaviours + SEP+BMIa
Blood pressure
Systolic (mm/Hg)b,c 4273 −0.04 (−0.46, 0.36) −0.27 (−0.69, 0.15)
Diastolic (mm/Hg)b,c 4273 0.06 (−0.14, 0.26) −0.02 (−0.23, 0.18)
Lipids
Total cholesterol (mMol/L) 4277 −0.00 (−0.02, 0.02) −0.00 (−0.02, 0.02)
HDL cholesterol (mMol/L) 4266 −0.00 (−0.01, 0.00) −0.00 (−0.01, 0.01)
Triglyceride (mMol/L)c,d 4176 0.00 (−0.00, 0.01) −0.00 (−0.01, 0.01)
Metabolic Markers
Body mass index (Kg/m2) 4295 0.16 (0.09, 0.23) 0.11 (0.04, 0.19)
Waist circumference (cm) 4203 0.44 (0.25, 0.63) 0.27 (0.08, 0.46)
Insulin (u/L)c,d 4192 0.01 (−0.00, 0.02) 0.00 (−0.01, 0.01)
Glucose (mMol/L)c,d 4162 0.002 (−0.004, 0.000) −0.002 (−0.005, 0.000)
Inﬂammatory/hemostatic markers
C-reactive protein (mg/L)d 4241 0.05 (0.03, 0.07) 0.03 (0.01, 0.05)
IL-6 (pg/mL)d 4267 0.03 (0.02, 0.04) 0.01 (0.00, 0.02)
White cell count (1ˆ09/L)c,d 4116 0.00 (−0.00, 0.01) 0.00 (−0.00, 0.01)
Albumin (g/L)c 4176 −0.09 (−0.14,−0.05) −0.07 (−0.12,−0.03)
Fibrin D-dimer (ng/mL)d 4282 0.00 (−0.01, 0.01) −0.01 (−0.02, 0.01)
Plasma viscosity (mPa s)c 4053 0.002 (0.001, 0.004) 0.001 (−0.000, 0.003)
Blood viscosity (mPa s)c,d 3978 0.003 (0.001, 0.004) 0.002 (−0.000, 0.003)
Fibrinogen (g/L)c 4176 0.02 (0.00, 0.03) 0.02 (0.00, 0.03)
Factor VII (IU/dL)c 4170 0.44 (−0.08, 0.96) 0.06 (−0.47, 0.59)
Factor VIII (IU/dL) 4279 1.41 (0.81, 2.00) 1.09 (0.48, 1.69)
Von Willebrand Factor (IU/dL) 4283 1.98 (1.20, 2.76) 1.75 (0.95, 2.54)
t-PA (ng/mL)c 4182 0.17 (0.11, 0.24) 0.08 (0.02, 0.15)
Mean platelet volume (fL) 4147 0.01(−0.02, 0.04) 0.00 (−0.03, 0.03)
Hematocrit (%) 4212 −0.05 (−0.11, 0.01) −0.06 (−0.12, −0.00)
Platelet count (1ˆ09/L) 4212 1.10 (−0.02, 2.24) 0.93 (−0.20, 2.10)
Homocysteine(mol/L)(men only) 2024 0.11 (−0.03, 0.24) 0.06 (−0.08, 0.20)
IL-18 (pg/mL)d 1349 0.01 (−0.01, 0.02) 0.01 (−0.01, 0.02)
CD40 Ligand (pg/mL)d 1355 0.01 (−0.01, 0.03) 0.01 (−0.01, 0.03)
MMP-9 (ng/mL)d 1355 0.01 (−0.01, 0.03) 0.01 (−0.01, 0.03)
TNF (pg/mL)d 1340 0.01 (−0.01, 0.03) 0.01 (−0.01, 0.03)
Results in bold reach conventional statistical signiﬁcance levels (5%).
a Adjusted for alcohol intake (six categories), smoking history (ﬁve categories), physical activity (inactive/active), SEP(manual, non-manual, armed forces), BMI (and
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b Adjusted for intra-observer variation.
c Adjusted for time of day.
d Natural log transformed: coefﬁcient reported for log variable represents a prop
.1. Strengths and weaknesses
This is the ﬁrst study to examine associations between serum
otinine levels in non-smokers and an exceptionally wide range of
stablished and novel CVD risk factors and beneﬁts from a large
opulation including both sexes sets results in context using active
mokers. Serum cotinine is an objective marker that is well vali-
ated tomeasure overall SHS exposure, which has advantages over
elf-reported exposure [18]. This study is unique in investigating a
arwider range of risk factors than the two earlier studieswith coti-
ine data [5,19]. A limitation is the inability to completely exclude
esidual confounding of associations between cotinine and CVD
arkers, particularly by socio-economic factors and adiposity.
.2. Other studies
Our data comparing risk factor levels between active smokers
nd non-smokers with undetectable cotinine are potentially less
iased than thoseofother studies,whichgenerally includedpartici-
ants exposed to SHS in thenon-smoker reference group.However,
verall the results are similar in showing that active smokers
ad lower BMI and waist circumference and albumin compared
ith non-smokers, but higher triglycerides [13–16], inﬂammatory,
emostatic and endothelial markers [13,27,28]. Our results for SHS
xposure, ﬁnding associations with biomarkers of inﬂammation,
emostasis and endothelial dysfunction rather than with estab-al change.
lished CHD risk factors are consistentwith an earlier report relating
self-reported SHS exposure of >1h/week to higher CRP and white
blood cell count, but not to BP or lipids [29], although other stud-
ies do report that SHS exposure is associated with lower HDLc [3].
Ourﬁndings indicating a generalised inﬂammatory response to SHS
exposure ﬁt with prior evidence that CRP is raised (with self-report
or cotinine) [17,30], although we did not observe elevated white
bloodcell counts reportedelsewhere [17,19,29]. Theobservedasso-
ciationsbetweenhemostatic factors (several ofwhicharealsoacute
phase reactants) and SHS exposure are consistentwith someearlier
data. Positive associations between SHS exposure (self-reported
or cotinine levels) and ﬁbrinogen levels have been reported pre-
viously [19,22]. Although associations between active smoking
and higher VWF levels have been reported previously [14,15],
our study appears to be the ﬁrst reporting associations with SHS
exposure. The association with VWF ﬁts with reports of impaired
ﬂow-mediated dilatation, a more direct measure of endothelial
dysfunction, in smokers than non-smokers and an inverse dose-
responseassociationofpoorerdilatationwithgreater SHSexposure
[12]. Active smoking is associated with elevated oxidative stress
which may in turn alter endothelial function, for instance through
reduced nitric oxide (NO) bioavailability, although data were not
available here to investigate these pathways for SHS exposure.
We did not replicate positive associations between SHS exposure
(self-reported or cotinine) and homocysteine [10,17,19], possibly
because we had fewer participants with homocysteine data.
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.3. Interpretation of results
SHS exposure exhibited graded trends with several, although
ot all inﬂammatory, hemostatic and endothelial markers which
re also related to active smoking. Selection bias in unlikely given
ur reasonably high response rates, as is misclassiﬁcation of active
mokers wrongly placed into high SHS group; participants with
levated cotinine (>15ng/ml) were excluded from SHS analyses.
esults are not affected by using a more conservative cotinine
hreshold for active smoking (9.5ng/ml) [31]. Restricting analyses
o self-reported never-smokers reduced power and adjusted asso-
iationswithBMI, CRP, IL-6, albuminandﬁbrinogenwereno-longer
igniﬁcant, bringing into question their causative roles. Residual
onfounding, particularly by social factors is possible despite sta-
istically controlling for social class. We speciﬁcally examined the
ffect of adjustment for social class after adjusting for behavioural
nd demographic factors and social class little affected the cotinine
oefﬁcient. Observed associations between SHS and endothelial,
nﬂammatory and hemostatic markers were somewhat attenuated
y adjustments, although CRP, VWF, tPA, ﬁbrinogen and albu-
in remained statistically signiﬁcant after adjustment for social,
ehavioural and established risk factors plus BMI. It is biologically
lausible that associations between SHS exposure and CVD risk
arkers are causal. The cardiovascular system is very sensitive to
HS and inﬂammation and platelet activation are prominent in the
esponse to SHS; ﬁbrinogen, VWF and t-PA aremarkers of both pro-
esses [3,19]. As in previous studies [19], the inﬂuence of SHS on
nﬂammatory and hemostatic markers starts at very low levels of
xposure (being apparent well below 0.7ng/ml, the cotinine level
ssociated with increased CHD risk in our earlier study [5]) and are
isproportionate to exposure levels. The magnitude of differences
nCRP, ﬁbrinogenandalbuminbetweenhighand lowSHSexposure
re around one-third to one half of the magnitude of differences
etween active smokers and low SHS exposure, although the dif-
erences are of similar magnitude for VWF and t-PA. Given current
vidence about the strengths of association of CRP, VWF and t-PA
o CHD risk [28,32,33], the potential impact of SHS exposure (coti-
ine ≤0.05 vs >0.7) acting through each pathway is approximately
–10% and could therefore be expected to affect population levels
f CHD. Several of the inﬂammatory and hemostatic factors have
een implicated in causation of type 2 diabetes [34] which would
e consistent with an earlier report implicating SHS exposure in
ype 2 diabetes [35].
. Conclusions
This study suggests that SHS exposure, even at very low levels
as important inﬂuences on endothelial, inﬂammatory and hemo-
tatic factors. The ﬁndings emphasize the continued importance of
fforts to reduce exposure to SHS, even at very low levels.
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